Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally

* Agreement combines Baird Medical's clinical, regulatory, and global commercialization expertise with Alpmed's leadership in IRE technology

* Collaboration will advance technology development, global regulatory approvals, commercialization, and clinical adoption across key international markets, including the United States NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”) and Tianjin Yuanshan Medical Technology Co., Ltd., operating under the Alpmed brand (“Alpmed”), a China-based innovator in irreversible electroporation (“IRE”) technology, announced the signing of a strategic cooperation agreement to establish a long-term partnership focused on global development and commercialization of next-generation IRE technologies.